<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03244358</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-010</org_study_id>
    <nct_id>NCT03244358</nct_id>
  </id_info>
  <brief_title>Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer</brief_title>
  <official_title>Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer:A Single Arm,Single Center,Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Epalrestat in the treatment of metastatic triple
      negative breast
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II,single center,prospective, single arm clinical trials. The objective is to
      evaluate the efficacy and safetyof Epalrestat in the treatment of metastatic triple negative
      breast.Primary endpoint is 16-week clinical benefit rate (CBR).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>30 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Epalrestat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epalrestat added to standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epalrestat</intervention_name>
    <description>Epalrestat 50mg tid added to standard chemotherapy treatment</description>
    <arm_group_label>Epalrestat</arm_group_label>
    <other_name>Tanglin (Yangtze River Pharmaceutical Group), China</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female ≥ 18 years, ≤70 years.

          -  Minimum life expectancy 16 weeks

          -  Histologicalconfirmation of hormone receptor negative and HER2 negative breast
             cancer(IHC:ER -, PR-) on primary tumour at diagnosis/on biopsy of metastasis

          -  Clinical or histological confirmation of metastatic or locally advanced disease not
             amenable to curative surgical resection

          -  ECOG 0-2 with no deterioration over previous 2 weeks Measurable disease

          -  Adequate bone marrow and organ function

          -  Availability of archival tumour sample or fresh biopsy Informed consent

          -  Normal organ function

        Exclusion Criteria:

          -  Last dose chemotherapy, immunotherapy targeted therapy, biological therapy or tumour
             embolisation &lt;21 days prior to study treatment

          -  Last dose of palliative radiotherapy &lt;7 days prior to study treatment

          -  Rapidly progressive visceral disease not suitable for further therapy

          -  Spinal cord compression or brain/meningeal metastases unless asymptomatic, treated and
             stable and not requiring steroids for ≥ 4 weeks study treatment

          -  Major surgery (excluding placement of vascular access) within 4 weeks before study
             treatment

          -  Evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension, active bleeding diatheses, or active infection including hepatitis B,
             hepatitis C and HIV

          -  With the exception of alopecia, any unresolved toxicities from previous therapy
             greater than CTCAE grade 1 before study treatment

          -  Elevated ALP in absence of bone metastasis

          -  Evidence of dementia, altered mental status or any psychiatric condition that would
             prohibit understanding or rendering of informed consent

          -  Participation in another study with investigational product during last 30 days

          -  Inability or unwillingness to comply with study procedures, including inability to
             take regular oral medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhongyu yuan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhongyu yuan, M.D.</last_name>
    <phone>86-20-87342496</phone>
    <email>yuanzhy@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University, Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan Zhong-yu, MD</last_name>
      <phone>86-20-87342496</phone>
      <email>yuanzhy@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Huang Jia-Jia, MD</last_name>
      <phone>86-20-87343794</phone>
      <email>huangjiaj@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yuan Zhong-yu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huang Jia-Jia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>professer</investigator_title>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Epalrestat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epalrestat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

